News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Teva sells women's health division to tackle $35bn debts Teva has sold its women’s health business in order to pay off some of its $35 billion in debts built up in acquiring Allergan’s generics business.
News Bidders lining up for Teva women's health unit Allergan generics buyout left Teva with $35m debts
News FDA's Gottlieb reveals plans to tackle generic price abuses Tackling high drug prices is priority for Trump administrations.
News Teva's CEO Vigodman steps down Firm searches for new leader, chairman takes over on interim basis.
Views & Analysis Making the case for pharmaceutical IP management IP management can protect pharma companies’ investments and future R&D.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
